ITCC Clinical Trials

Open Label, Pilot Phase II Study of Glivec? in Children and Adolescents with Life Threatening Diseases Known to be Associated with one or more Glivec?-Sensitive Tyrosine Kinases -1st European Glivec - Pediatric Study

A Phase I-II Clinical and Pharmacokinetic Study of APLIDIN® (APL) as a 3-hour Intravenous Infusion every 2 Weeks, in Children with Refractory or Relapsed Malignant Tumors

Phase I studies of TarcevaTM (Erlotinib hydrochloride, OSI-774) as single agent in children with refractory or relapsed malignant brain tumors and in combination with irradiation in newly diagnosed brain stem glioma

Phase 2 Single-arm Studies of Gemcitabine in Combination with Oxaliplatin in Patients with Refractory and Relapsed Pediatric Solid Tumors

Phase I study of Src/Abl tyrosine kinase inhibitor dasatinib [BMS-354825] in children and adolescents with relapsed or refractory leukemia

Open-label, multi-center, randomized, phase II study evaluating the addition of bevacizumab to standard chemotherapy in childhood and adolescent patients presenting with metastasized RMS and non-RMS soft tissue sarcoma EpssG/BO20924 BERNIE

A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma

Phase 2 Single-Arm, Open Label Study of Irinotecan in Combination with Temozolomide in Children with Recurrent or Refractory Medulloblastoma and in Children with newly diagnosed high-grade glioma.

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

A Phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas

Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours

A Phase I Study of MK-8669 (Ridaforolimus) in Pediatric Patients with Advanced Solid Tumors

A Phase I Study of MK-8669 (Ridaforolimus) and MK-0646 (Dalotuzumab) in Pediatric Patients with Advanced Solid Tumors

A phase I/II study of Azacytidine (VIDAZA®) in pediatric patients with relapsed high-grade pediatric MDS or JMML

ATRIGE/A4021020

Phase 2 study of CP-751,871 in patients with relapsed and/or refractory Ewing’s sarcoma family of tumors A4021020

An open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma

A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML

Bortezomib (Velcade®): A feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia

Phase I-II Study of Vinblastine in combination with Nilotinib in children and adolescents with refractory or recurrent low-grade glioma : A SIOP and ITCC protocol

A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients

International randomized phase II trial of the combinations of vincristin and irinotecan with or without temozlomide (VI or VIT) in patients with refractory or relapsed rhabdomyosarcoma

Combined dose ranging and randomised, comparative open label study of the efficacy and safety of plerixafor in addition to standard regimens for mobilisation of haematopoietic stem cells into peripheral blood

A single-arm multicenter phase II study preceded by dose evaluation to investigate the efficacy, safety, and tolerability of the BiTE® Antibody Blinatumomab (MT103) in pediatric and adolescent patients

A Phase I Study of LDE225 in Pediatric Patients with Recurrent or Refractory Medulloblastoma, and other tumors potentially dependent on Hedgehog signaling

A randomized phase IIb trial of Bevacizumab added to Temozolomide ± Irinotecan for children with refractory/relapsed neuroblastoma

Beacon-Neuroblastoma Trial (Beacon Immuno) Dinutuximab beta [dB] randomisation

A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC

A Phase 2 study of Ipilimumab in Children and Adolescents (12 to < 18 years) with Previously Treated or Untreated Stage III or Stage IV Malignant Melanoma

A Phase III, multi-center, open-label, randomized, controlled study of the efficacy and safety of oral LDE225 versus temozolomide (TMZ) in patients with Hedgehog(Hh)-pathway activated relapsed medulloblastoma

Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors

A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability and preliminary efficacy of weekly nab®-paclitaxel in pediatric subjects with recurrent or refractory solid tumors.

A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)

A phase I, multi-center, open-label study of LEE011 in patients with malignant rhabdoid tumors and neuroblastoma

A Phase I/II, open-label, multi-center, dose-finding, safety and efficacy study of parenteral azacitidine (Vidaza®) as an epigenetic priming treatment

Phase 1-2 safety and efficacy study of DACOGEN in sequential combination with cytarabine in children with refractory or relapsed acute myeloid leukaemia

Open, dose finding Phase I trial to investigate the paediatric dose, tolerability and pharmacokinetics of single and multiple doses of volasertib in children

Open, dose finding Phase I trial to investigate the paediatric dose, tolerability and pharmacokinetics of single and multiple doses of volasertib in children

A multi-centre, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in paediatric patients

A Phase 1, multi-center, open-label, non-randomized, dose escalation design study of regorafenib (BAY 73-4506) in paediatric patients from 6 months to less than 18 years with a solid malignant tumour refractory to standard therapy.

A Phase 1, multi-center, open-label, non-randomized, dose escalation cohort expanding study of regorafenib (BAY 73-4506) in paediatric patients from 6 months to less than 18 years with a solid malignant tumour refractory to standard therapy

Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years

Phase 1/2 Study of Lenvatinib (E7080) in Children and Adolescents with Relapsed or Refractory Solid Malignancies

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication : BIOMEDE

Phase 1b/2 Study of Carfilzomib in combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (R3 Induction Backbone) in pediatric subjects with relapsed or refractory Acute Lymphoblastic Leukemia

A phase IB study of crizotinib (Xalcori®) in pediatric malignancies with anaplastic lymphoma kinase (ALK) aberrations

A phase I/II study of Bosutinib in pediatric patients with Chronic Myeloid Leukemia who are resistant or intolerant to at least one prior Tyrosine Kinase Inhibitor therapy

A Phase I/II, Multicenter, Open-Label, dose‑escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously treated Solid Tumors

A Prospective, Multicentric Clinical Proof-of-Concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors

A Prospective, Multicentric Clinical Proof-of-Concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in children (ESMART)

A PHASE I/II, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI-PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS

T2015-001 A phase I study of Inotuzumab Ozogamycin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

A Phase 1 Study of EPZ-6438 (an EZH2 Inhibitor) in Pediatric Patients with Relapsed/Refractory INI1-Negative Tumors or Synovial Sarcomas

Multicentre, open label, single arm Phase II study of Pegylated recombinant human arginase (BCT-100) in children > 1 year and <18 years with solid tumours, CNS malignancies and leukemias that are recurrent or refractory to standard therapy

A phase IB/II open label study of the MEK-inhibitor selumetinib in combination with dexamethasone for paediatric and adolescent patients with ≥2nd relapsed precursor B or T ALL

ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Ibrutinib randomized safety and efficacy study in pediatric patients with mature B-cell NHL, including Burkitt lymphoma/Leukemia and Diffuse Large B-cell Lymphoma

A Phase I/II Study of the Oral TRK Inhibitor LOXO 101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

A phase I/II, multi-center, dose-escalating study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of Quizartinib administered in combination with re-induction chemotherapy, and as a single-agent maintenance therapy

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric Patients with Select Relapsed or Refractory Malignancies

An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age with Relapsed/Refractory Precursor B-cell or T cell Acute Lymphoblastic Leukemia

INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies

Pilot study of nivolumab in paediatric patients with hypermutant cancers

Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with PD or as consolidative immunotherapy in patients in CR after relapse

A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone/Bone Marrow

Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies

A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients (aged 6 months to 17 years) with Solid Tumours

PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN CHILDREN AND ADOLESCENTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION, RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS

A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN

Phase 2 study to compare the efficacy and safety of lenvatinib (LEN) in combination with ifosfamide (IFO) and etoposide (ETO) versus IFO and ETO in patients with R/R osteosarcoma

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

A Phase 1b, Dose Escalation Study of Abemaciclib in Combination with Temozolomide and Irinotecan (triplet escalation) and Abemaciclib in combination with Temozolomide (doublet escalation) in Pediatric and Young Adult Patients with R/R Solid Tumours

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma

FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML

A Phase Ib/II study of AsiDNA™ in association with re-irradiation in paediatric high-grade glioma

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations

A PHASE I/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ALECTINIB IN RELAPSED OR REFRACTORY PEDIATRIC PATIENTS WITH ALK FUSION-POSITIVE SOLID OR CNS TUMORS

A Phase I/II study of Brigatinib as monotherapy in pediatric and young adult patients with ALK-positive Anaplastic Large Cell Lymphoma (ALCL) , Inflammatory Myofibroblastic Tumors (IMT) or other solid tumors

A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumours